Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose Escalation Study of CCT3833 in Advanced Solid Tumours and Melanoma
NCT02437227Phase 1Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Apr 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CCT3833 in solid tumor and melanoma (8 cohorts), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Dose Limiting Toxicities at 18 months and Adverse Events at 18 months. Started Apr 2015; status: completed.
02
Drugs
CCT3833
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT02437227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02437227.